Health Care · Pharmaceutical Preparations

PGEN PRECIGEN, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1356090110 filings
Russell 2000

PGEN at a glance

PRECIGEN, INC. (PGEN, SEC CIK 1356090) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), PRECIGEN, INC. (PGEN) reported revenue of $9.7 million (up 146.7% from FY2024) and a net loss of $250.6 million. Diluted EPS was -$1.37.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding PRECIGEN, INC. (PGEN) shares worth $469.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by KINDLER JEFFREY B on August 26, 2026 of 185,000 shares at $7.44 per share.
  • In the last 90 days, PGEN insiders reported 0 open-market purchases ($0) and 3 open-market sales ($2.1M) on Form 4, a net sale of $2.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$9.7M
+146.7% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$2.1M
13F holders
26 funds
$469.4M · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $74.1M, up >200% YoY from $2.9M, driven by Papzimeos product revenue of $72.9M
  • Operating margin 52.1% vs (1,180.4)% YoY, with operating income $38.7M vs loss of $34.5M
  • Papzimeos strongest product line, $72.9M revenue; collaboration and licensing revenue weakest, $0 vs $1.8M YoY
  • Q3 operating cash flow $11.9M positive; September 30 cash $15.0M plus investments of $36.0M
  • Outlook: continued Papzimeos commercialization, with headwinds from 127-day customer payment terms and potential additional capital needs

Risk Factors

  • No additional material risk-factor changes since the Annual Report
  • Carried-forward risks may materially affect operating results
  • Carried-forward risks may materially affect financial condition
  • SEC filings contain additional relevant risk disclosures

AI summary of the PGEN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Exhibit 99.1 announces Precigen’s financial results for the quarter ended September 30, 2026
  • Investor focus: quarterly performance metrics, cash position and management commentary in the attached earnings release

Item EX-99.1: Item EX-99.1

  • Q3 2026 PAPZIMEOS revenue $72.9M, up 37% sequentially, confirming accelerating commercial adoption
  • Positive operating cash flow $11.9M, one quarter ahead of guidance, reducing near-term financing pressure
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Exhibit 99.1 contains Precigen’s financial results for the quarter ended June 30, 2026
  • August 4, 2026 press release provides the substantive earnings details

Item EX-99.1: Item EX-99.1

  • PAPZIMEOS revenue reached $53.1 million in Q2, more than doubling from the prior quarter and driving quarterly net income of $20.1 million
  • Total revenue rose to $55.0 million from $0.9 million, while operating income reached $22.6 million versus a $31.8 million loss
Filed Jun 24, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Stockholders approved 7 million additional shares under Precigen’s 2023 Omnibus Incentive Plan
  • Expanded equity capacity supports future employee and executive compensation

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All nine director nominees elected for one-year terms, preserving board continuity
  • Vinita Gupta faced strongest opposition, with 57,856,824 votes against

AI summaries of PGEN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PGEN

Don't miss the next PGEN filing

  • Alerts as it files. A push when PGEN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PGEN, by share count.
  • Ask anything. An AI agent that reads every PGEN filing and answers with sources.

PGEN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Thomasian Harry Jr.MSep 23, 2026-
Thomasian Harry Jr.MSep 23, 2026-
Thomasian Harry Jr.MSep 23, 2026-
Thomasian Harry Jr.MSep 23, 2026-
Thomasian Harry Jr.MSep 23, 2026$2.33
Thomasian Harry Jr.MSep 23, 2026$4.72
Thomasian Harry Jr.MSep 23, 2026$1.21
Thomasian Harry Jr.MSep 23, 2026$0.96

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$3.9M$9.7M
Operating Income-$99.8M-$135.0M-$110.5M
Net Income-$95.9M-$126.2M-$250.6M
Op. Margin--3440.2%-1141.1%
Net Margin--3216.2%-2588.2%
Balance Sheet
Total Assets-$145.3M$155.5M
Equity-$38.5M$20.9M
ROE--327.8%-1198.6%
Per Share
EPS-$-0.47$-1.37
Cash Flow
Operating CF-$66.9M-$68.2M-$87.8M
CapEx$1.5M$8.6M$2.0M

Source: XBRL data in PRECIGEN, INC. (PGEN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PGEN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PGEN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$469.4M
Q2 202626$334.7M
Q1 202623$209.2M
Q4 202520$236.6M
Q3 202523$130.5M
Q2 202523$44.3M
Q1 202523$26.2M
Q4 202418$16.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 182 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PGEN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 5, 2026Analysis-
10-QNov 4, 2026Analysis
4Sep 24, 2026--
4Aug 28, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 7, 2026--
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
4Aug 3, 2026--
4Jul 31, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
8-KJun 24, 2026Analysis-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4May 27, 2026-

Related Health Care companies

All Health Care →

PGEN SEC filings: frequently asked questions

Are PGEN insiders buying or selling?

In the last 90 days, PRECIGEN, INC. (PGEN) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $2.1 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PGEN stock?

As of September 30, 2026, the largest PRECIGEN, INC. (PGEN) holders among the 13F filers tracked by SignalX were BlackRock ($147.9 million), State Street Corp ($91.8 million), Vanguard Capital Management LLC ($68.6 million), Morgan Stanley ($35.4 million), Vanguard Portfolio Management LLC ($19.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PGEN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), PRECIGEN, INC. (PGEN) reported revenue of $9.7 million (up 146.7% from FY2024) and a net loss of $250.6 million. Diluted EPS was -$1.37. The figures come from the XBRL data in the 10-K.

What did PGEN report in its latest 8-K?

PRECIGEN, INC. (PGEN) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 announces Precigen’s financial results for the quarter ended September 30, 2026.

What are the latest PGEN SEC filings?

PRECIGEN, INC. (PGEN) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 24, 2026.

What is PGEN's SEC CIK number?

PRECIGEN, INC. (PGEN)'s SEC Central Index Key (CIK) is 1356090. EDGAR lists every PGEN filing under that number.

Ask anything about PGEN

The research agent reads PGEN's filings, financials, insider trades and 13F holders, then answers with sources.